Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

07 nov. 2016 12h39 HE | Source: Coherus BioSciences, Inc.

Coherus BioSciences Receives Decision Denying Institution of the ‘166 IPR Related to AbbVie’s HUMIRA® Formulation

REDWOOD CITY, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that it has received a decision from the Patent Trial and Appeal Board (PTAB) of...
04 nov. 2016 16h30 HE | Source: Coherus BioSciences, Inc.

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective November 4, 2016, the compensation committee of the company’s board...
01 nov. 2016 16h30 HE | Source: Coherus BioSciences, Inc.

Coherus BioSciences to Report Third Quarter 2016 Financial Results on November 9th

REDWOOD CITY, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its third quarter 2016 financial results will be released on November 9,...
01 nov. 2016 09h00 HE | Source: Coherus BioSciences, Inc.

Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in November

REDWOOD CITY, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at two upcoming investor healthcare conferences...
21 oct. 2016 09h00 HE | Source: Coherus BioSciences, Inc.

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Oct. 21, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective October 20, 2016, the compensation committee of the company’s board...
06 oct. 2016 17h53 HE | Source: Coherus BioSciences, Inc.

Coherus BioSciences Announces FDA Acceptance of 351(k) Biologics License Application to U.S. Food and Drug Administration for CHS-1701 (Pegfilgrastim Biosimilar Candidate)

REDWOOD CITY, Calif., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), a leading pure-play, global biosimilar company with late-stage clinical products, today...
06 oct. 2016 16h08 HE | Source: Coherus BioSciences, Inc.

Coherus BioSciences Completes two Pharmacokinetic Bioequivalence Studies of CHS-0214

REDWOOD CITY, Calif., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) a leading pure-play, global biosimilar company with late-stage clinical products, today announced...
27 sept. 2016 08h00 HE | Source: Coherus BioSciences, Inc.

Coherus BioSciences Regains Development and Commercial Rights to CHS-0214 From Shire

REDWOOD CITY, Calif., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that it has regained from Shire plc all development and commercial rights previously...
16 sept. 2016 19h00 HE | Source: Coherus BioSciences, Inc.

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Sept. 16, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective September 16, 2016, the compensation committee of the company’s...
01 sept. 2016 14h00 HE | Source: Coherus BioSciences, Inc.

Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in September

REDWOOD CITY, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at two upcoming investor healthcare...

Page précédente